Dermira Inc  

(Public, NASDAQ:DERM)   Watch this stock  
Find more results for Kathleen Sebelius´┐Ż
-0.05 (-0.16%)
Real-time:   11:55AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 31.02 - 31.77
52 week 17.42 - 35.75
Open 31.74
Vol / Avg. 47,629.00/310,794.00
Mkt cap 1.08B
P/E     -
Div/yield     -
EPS -3.27
Shares 34.50M
Beta     -
Inst. own 79%
Aug 11, 2016
Q2 2016 Dermira Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 1, 2016
Dermira, Inc. Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in Patients with Primary Axillary Hyperhidrosis - Webcast
May 10, 2016
Q1 2016 Dermira Inc Earnings Release
May 10, 2016
Dermira Inc Conference Call To Discuss DRM01 Phase 2b Clinical Trial Results - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -1073.96%
Operating margin - -1092.74%
EBITD margin - -1057.26%
Return on average assets -54.48% -39.18%
Return on average equity -66.05% -46.25%
Employees 62 -
CDP Score - -


275 Middlefield Rd Ste 150
MENLO PARK, CA 94025-4008
United States - Map
+1-650-4217200 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Dermira, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company's portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor, that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. DRM04 is a topical, small-molecule anticholinergic product for the treatment of hyperhidrosis. DRM01 is a topical, small-molecule sebum inhibitor for the treatment of acne.

Officers and directors

Christopher M. Griffith MBA Founder, Vice President - Corporate Development and Strategy
Age: 38
Bio & Compensation  - Reuters
Luis C. Pena Founder, Chief Development Officer
Age: 52
Bio & Compensation  - Reuters
Andrew L. Guggenhime Chief Financial Officer, Chief Operating Officer
Age: 46
Bio & Compensation  - Reuters
Thomas G. Wiggans Chairman of the Board, Chief Executive Officer, Founder
Age: 63
Bio & Compensation  - Reuters
Eugene A. Bauer M.D. Founder, Chief Medical Officer, Director
Age: 72
Bio & Compensation  - Reuters
Mark D. McDade Director
Age: 59
Bio & Compensation  - Reuters
Kathleen Sebelius Director
Bio & Compensation  - Reuters
David E. Cohen M.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
Frederick B. Craves Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Matthew K. Fust Independent Director
Age: 50
Bio & Compensation  - Reuters